Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
69,311.41 +1,751.93 (+2.59%) CMC Crypto 200
1,393.52 +62.91 (+4.73%)
Fagron NV (0HNZ.IL)
| Previous close | 18.54 |
| Open | 18.70 |
| Bid | 18.06 x 0 |
| Ask | 19.44 x 0 |
| Day's range | 18.70 - 18.74 |
| 52-week range | 15.49 - 19.08 |
| Volume | |
| Avg. volume | 34,551 |
| Market cap | 1.364B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 19.91 |
| EPS (TTM) | 0.93 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | 0.25 (1.57%) |
| Ex-dividend date | 15 May 2023 |
| 1y target est | N/A |
GlobeNewswireFagron shareholders approve all voting items at AGM and EGM
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders and extraordinary general meeting of shareholders today. Both meetings approved all. voting items. ResolutionsThe annual general meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.30
- GlobeNewswire
Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial statements and the
- GlobeNewswire
Record revenue of €209 million in first quarter reflecting 15% topline growth
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024. Key Highlights Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regionsOrganic growth at CER of 12.3%
